Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter, Genpathway Collaborate on ChIP-Seq Services

NEW YORK (GenomeWeb News) – Beckman Coulter Genomics, the genomics services subsidiary of Beckman Coulter, today said that it is teaming up with Genpathway to offer customers whole-genome chromatin immunoprecipitation sequencing (ChIP-Seq) services.

ChIP-Seq combines chromatin immunoprecipitation with ultra high-throughput next-generation DNA sequencing, enabling researchers to study complex interactions between proteins and nucleic acids. The services that the firms will offer will include ChIP experimental design and consultation, antibody qualification, performance of ChIP assays with post-ChIP QC, next-generation sequencing, and comprehensive data analysis, according to Danvers, Mass.-based Beckman Coulter Genomics.

"This dynamic new alliance is a natural fit, coupling Beckman Coulter Genomics' sequencing and marketing capabilities with Genpathway's ChIP experience to offer the global research community an expert source of ChIP sequencing data and analysis," Patrick Mallon, CEO of San Diego-based Genpathway, said in a statement.

Among Beckman Coulter Genomics' services are Sanger and next-gen sequencing, gene expression profiling, genotyping, and biologics testing.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.